Zacks Research Issues Optimistic Estimate for CRDF Earnings

Cardiff Oncology, Inc. (NASDAQ:CRDF) – Research analysts at Zacks Research increased their Q3 2026 earnings per share (EPS) estimates for Cardiff Oncology in a report released on Monday, August 17th. Zacks Research analyst J. Vandermosten now forecasts that the company will post earnings per share of ($0.15) for the quarter, up from their prior estimate of ($0.18). The consensus estimate for Cardiff Oncology’s current full-year earnings is ($0.65) per share. Zacks Research also issued estimates for Cardiff Oncology’s Q4 2026 earnings at ($0.17) EPS, FY2026 earnings at ($0.64) EPS, FY2027 earnings at ($0.57) EPS and FY2028 earnings at ($0.55) EPS.

Several other research analysts also recently commented on the stock. Weiss Ratings raised shares of Cardiff Oncology from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Wednesday, August 5th. William Blair cut shares of Cardiff Oncology from an “outperform” rating to a “market perform” rating in a research note on Tuesday, August 11th. Craig Hallum lowered shares of Cardiff Oncology from a “buy” rating to a “hold” rating and set a $2.00 target price on the stock. in a report on Wednesday, June 3rd. TD Cowen cut shares of Cardiff Oncology from a “buy” rating to a “hold” rating in a research report on Monday, June 1st. Finally, Wall Street Zen downgraded shares of Cardiff Oncology from a “hold” rating to a “sell” rating in a research note on Saturday, May 16th. Two investment analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $7.50.

Cardiff Oncology Price Performance

Shares of CRDF opened at $0.90 on Thursday. Cardiff Oncology has a 1 year low of $0.76 and a 1 year high of $3.31. The stock has a 50 day simple moving average of $1.10 and a two-hundred day simple moving average of $1.49. The firm has a market cap of $69.85 million, a P/E ratio of -1.50 and a beta of 1.49.

Cardiff Oncology (NASDAQ:CRDF) last posted its quarterly earnings data on Tuesday, August 11th. The company reported ($0.14) earnings per share for the quarter, missing the consensus estimate of ($0.12) by ($0.02). Cardiff Oncology had a negative net margin of 7,885.43% and a negative return on equity of 103.10%. The company had revenue of $0.10 million for the quarter, compared to analysts’ expectations of $0.06 million.

Insider Activity at Cardiff Oncology

In related news, CEO Mani Mohindru purchased 24,703 shares of the firm’s stock in a transaction on Thursday, June 18th. The shares were acquired at an average cost of $1.21 per share, with a total value of $29,890.63. Following the purchase, the chief executive officer directly owned 24,703 shares of the company’s stock, valued at approximately $29,890.63. This trade represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Gary W. Pace purchased 30,000 shares of the firm’s stock in a transaction on Thursday, June 18th. The stock was bought at an average cost of $1.22 per share, for a total transaction of $36,600.00. Following the completion of the purchase, the director directly owned 1,356,376 shares in the company, valued at approximately $1,654,778.72. This trade represents a 2.26% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. 8.50% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in the company. Bank of New York Mellon Corp bought a new stake in Cardiff Oncology during the 2nd quarter valued at $210,000. Bank of America Corp DE grew its holdings in Cardiff Oncology by 23.9% in the 1st quarter. Bank of America Corp DE now owns 51,119 shares of the company’s stock worth $83,000 after acquiring an additional 9,855 shares during the last quarter. BlackRock Inc. bought a new stake in Cardiff Oncology in the 2nd quarter worth $1,265,000. Ieq Capital LLC purchased a new position in shares of Cardiff Oncology in the second quarter valued at about $58,000. Finally, Capstone Investment Advisors LLC purchased a new position in shares of Cardiff Oncology in the second quarter valued at about $67,000. 16.29% of the stock is owned by hedge funds and other institutional investors.

Cardiff Oncology Company Profile

Cardiff Oncology, Inc is a clinical-stage biopharmaceutical company headquartered in Cambridge, Massachusetts. The company is dedicated to the discovery, development and commercialization of novel small-molecule therapies designed to modulate the tumor microenvironment and enhance antitumor immune responses. By focusing on unique immuno-oncology targets, Cardiff seeks to address resistance pathways that limit the effectiveness of existing cancer treatments.

Cardiff’s pipeline comprises several small-molecule immunomodulators in various stages of preclinical and clinical development.